Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Spero Therapeutics has raised $9.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2022.
Spero Therapeutics's investors include RA Capital Management, Pfizer, National Science Foundation, Rock Springs Capital, SR One.
Spero Therapeutics is headquartered in Cambridge, United States.
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Spero Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Spero Therapeutics — Funding & Investors." VCBacked, September 22, 2022, https://www.vcbacked.co/company/spero-therapeutics. Accessed July 19, 2026.
VCBacked. (2022). Spero Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/spero-therapeutics
{{cite web |title=Spero Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/spero-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated